AAVB-039

PreclinicalGene therapy

AAAVantgarde Bio Srl

AAVB-039 is one of 2 biologic programs targeting Stargardt Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stargardt DiseaseRecruiting

Stargardt DiseasePreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Stargardt Disease

#DrugCompanyPhaseTrials

ALK-001

AAlkeus Pharmaceuticals, Inc.

Phase 3

3 2

AAVB-039

AAAVantgarde Bio Srl

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2032

PreclinicalRecruiting

Stargardt Disease

NCT07161544

Clinical

Trials by Indication[1]

Stargardt Disease1 trial

An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants With Stargardt Disease (STGD1) (CELESTE)

Recruiting·AAAVantgarde Bio Srl·Preclinical·NCT07161544·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AAVB-039. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AAVB-039 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AAVB-039. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AAVantgarde Bio Srl company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Preclinical[1]
Company: AAAVantgarde Bio Srl

AAVB-039

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2032

Trials by Indication[1]

Stargardt Disease1 trial

References

Drug Info

Quick Facts

Related News